retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.

PURPOSE The aim of the study was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients. PATIENTS AND METHODS In the Danish Breast Cancer Cooperative Group trial 89D, 980 pre- and postmenopausal primary patients were randomly allocated to either CMF (cyclophosphamide, methotrexate, and fluorouracil; n = 500) or CEF (cyclophosphamide, epirubicin, and fluorouracil; n = 480) times 9, between January 1990 and November 1999. Tumor tissue was retrospectively identified from 805 patients and was analyzed for HER2-positivity and for TOP2A-amplifications and deletions. RESULTS HER2-positivity was found in 33% of the 805 investigated tumors and was not a predictive marker for epirubicin sensitivity. TOP2A changes were identified in 23% of the 773 investigated tumors: 12% had TOP2A amplifications and 11% had TOP2A deletions. We found that patients with TOP2A amplification had an increased recurrence-free (RFS; hazard ratio [HR], 0.43; 95% CI, 0.24 to 0.78) and overall survival (OS; HR, 0.57; 95% CI, 0.29 to 1.13), respectively if treated with CEF compared with CMF, and that patients with TOP2A deletions had an almost identical hazard ratio (RFS: HR, 0.63; 95% CI, 0.36 to 1.11; OS: HR, 0.56; 95% CI, 0.30 to 1.04). This is in contrast to patients with a normal TOP2A genotype for whom similar outcome was observed in both treatment arms (RFS: HR, 0.90; 95% CI, 0.70 to 1.17; OS: HR, 0.88; 95% CI, 0.66 to 1.17). CONCLUSION TOP2A amplification-and possibly deletion-seems to be predictive markers for the effect of adjuvant epirubicin containing therapy in primary breast cancer, but a final conclusion has to await a confirmative study or a meta-analysis.

[1]  J. Bergh,et al.  Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin , 1999 .

[2]  J. Kononen,et al.  Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. , 1996, The American journal of pathology.

[3]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[4]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Paik,et al.  HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. , 2000, Journal of the National Cancer Institute.

[6]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[7]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[8]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[9]  D. Larsimont,et al.  HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Cummings,et al.  DNA topoisomerase I and II as targets for rational design of new anticancer drugs. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Larsimont,et al.  HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Sehwan Han,et al.  Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. , 2003, European journal of cancer.

[13]  C. Sotiriou,et al.  Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. , 2004, International journal of oncology.

[14]  J. Isola,et al.  Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.

[15]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[16]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[17]  P. Ravdin.  Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes. , 2001, Journal of the National Cancer Institute. Monographs.

[18]  Jorma Isola,et al.  Characterization of topoisomerase IIα gene amplification and deletion in breast cancer , 1999 .

[19]  E. Liu,et al.  Effects of HER-2/neu on chemosensitivity of tumor cells. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[20]  S. Withoff,et al.  Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. , 1996, British Journal of Cancer.

[21]  J. Isola,et al.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. , 1998, British Journal of Cancer.

[22]  T. Petit,et al.  Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. , 2004, European journal of cancer.

[23]  S. Ménard,et al.  HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Preisler,et al.  Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Å. Borg,et al.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. , 2000, The American journal of pathology.

[26]  E. Balslev,et al.  Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes , 2004, Acta oncologica.